Source:http://linkedlifedata.com/resource/pubmed/id/19926128
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2010-1-29
|
pubmed:abstractText |
Regenerating bone tissue involves complex, temporal and coordinated signal cascades of which bone morphogenic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF(165)) play a prominent role. The aim of this study was to determine if the delivery of human bone marrow stromal cells (HBMSC) seeded onto VEGF(165)/BMP-2 releasing composite scaffolds could enhance the bone regenerative capability in a critical sized femur defect. Alginate-VEGF(165)/P(DL)LA-BMP-2 scaffolds were fabricated using a supercritical CO(2) mixing technique and an alginate entrapment protocol. Increased release of VEGF(165) (750.4+/-596.8 rho g/ml) compared to BMP-2 (136.9+/-123.4 r hog/ml) was observed after 7-days in culture. Thereafter, up till 28 days, an increased rate of release of BMP-2 compared to VEGF(165) was observed. The alginate-VEGF(165)/P(DL)LA-BMP-2+HBMSC group showed a significant increase in the quantity of regenerated bone compared to the alginate-VEGF(165)/P(DL)LA-BMP-2 and alginate/P(DL)LA groups respectively in a critical sized femur defect study as indices measured by microCT. Histological examination confirmed significant new endochondral bone matrix in the HBMSC seeded alginate-VEGF(165)/P(DL)LA-BMP-2 defect group in comparison to the other groups. These studies demonstrate the ability to deliver a combination of HBMSC with angiogenic and osteogenic factors released from biodegradable scaffold composites enhances the repair and regeneration of critical sized bone defects.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/BMP2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Bone Morphogenetic Protein 2,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1878-5905
|
pubmed:author | |
pubmed:copyrightInfo |
(c) 2009 Elsevier Ltd. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1242-50
|
pubmed:meshHeading |
pubmed-meshheading:19926128-Adult,
pubmed-meshheading:19926128-Animals,
pubmed-meshheading:19926128-Bone Morphogenetic Protein 2,
pubmed-meshheading:19926128-Cell Differentiation,
pubmed-meshheading:19926128-Cells, Cultured,
pubmed-meshheading:19926128-Drug Combinations,
pubmed-meshheading:19926128-Femoral Fractures,
pubmed-meshheading:19926128-Humans,
pubmed-meshheading:19926128-Mesenchymal Stem Cell Transplantation,
pubmed-meshheading:19926128-Mesenchymal Stem Cells,
pubmed-meshheading:19926128-Mice,
pubmed-meshheading:19926128-Osteoblasts,
pubmed-meshheading:19926128-Osteogenesis,
pubmed-meshheading:19926128-Treatment Outcome,
pubmed-meshheading:19926128-Vascular Endothelial Growth Factor A
|
pubmed:year |
2010
|
pubmed:articleTitle |
The effect of the delivery of vascular endothelial growth factor and bone morphogenic protein-2 to osteoprogenitor cell populations on bone formation.
|
pubmed:affiliation |
Bone & Joint Research Group, Centre for Human Development, Stem Cells and Regeneration, Developmental Origins of Health and Disease, Institute of Developmental Sciences, University of Southampton, General Hospital, Southampton, SO16 6YD, UK.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|